[Antibody-drug conjugate--a new age for personalized cancer treatment].
LCMC Lonza AG, Rottenstrasse 6, CH-3930 Visp. iwan.bertholjotti@lonza.com
Iwan
I
Bertholjotti
D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008453:Maytansine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D057285:Precision Medicine / Q000379:methods*; D000068878:Trastuzumab; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D008453:Maytansine; D000079963:Brentuximab Vedotin; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine